Assessment of progesterone receptors in breast carcinoma by PET with 21- 18F-fluoro-16α,17α-[(R)-(1′-α- furylmethylidene) dioxy]-19-norpregn-4-ene-3,20-dione

Journal of Nuclear Medicine

Volumn 53, Issue 3, 2012, Pages 363-370

  Dehdashti, Farrokh ^a,b,c   Laforest, Richard ^a,b,c   Gao, Feng ^b,c,d   Aft, Rebecca L ^b,c,d   Dence, Carmen S ^a,c   Zhou, Dong ^a,c   Shoghi, Kooresh I ^a,b,c   Siegel, Barry A ^a,b,c   Katzenellenbogen, John A ^d   Welch, Michael J ^a,b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MO   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Breast cancer; PET; Progesterone receptor

Indexed keywords

21 FLUORO 16ALPHA,17ALPHA [(1' ALPHA FURYLMETHYLIDENE) DIOXY] 19 NORPREGN 4 ENE 3,20 DIONE F 18; ESTROGEN RECEPTOR; FLUORINE 18; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DOSIMETRY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE DISPLAY; IN VITRO STUDY; IN VIVO STUDY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MIDDLE AGED; NORPREGNENES; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTORS, PROGESTERONE; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 84858588947     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.098319     Document Type: Article

References (40)

1. Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: Prognosis and prediction. Endocr Relat Cancer. 2010;17:R245-R262.
2. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004;6:109-118. (Pubitemid 38607664)
3. Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer-the present. Histopathology. 2008;52:82-90. (Pubitemid 350265187)
4. Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer. 2005;103:2241-2251. (Pubitemid 40686567)
5. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687-1717.
6. Keen JC, Davidson NE. The biology of breast carcinoma. Cancer. 2003;97:825-833. (Pubitemid 36125819)
7. Goldhirsch A, Colleoni M, Gelber RD. Endocrine therapy of breast cancer. Ann Oncol. 2002;13(suppl 4):61-68. (Pubitemid 35369974)
8. Rhodes A, Jasani B, Balaton AJ, Miller KD. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol. 2000;53:292-301. (Pubitemid 30180402)
9. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134:e48-e72.
10. Lee JH, Zhou HB, Dence CS, Carlson KE, Welch MJ, Katzenellenbogen JA. Development of [f-18]fluorine-substituted tanaproget as a progesterone receptor imaging agent for positron emission tomography. Bioconjug Chem. 2010; 21:1096-1104.
11. Kochanny MJ, VanBrocklin HF, Kym PR, et al. Fluorine-18-labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors. J Med Chem. 1993;36:1120-1127. (Pubitemid 23159285)
12. Buckman BO, Bonasera TA, Kirschbaum KS, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled progestin 16 alpha, 17 alpha-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity. J Med Chem. 1995;38:328-337.
13. Kym PR, Carlson KE, Katzenellenbogen JA. Progestin 16 alpha, 17 alpha-dioxolane ketals as molecular probes for the progesterone receptor: synthesis, binding affinity, and photochemical evaluation. J Med Chem. 1993;36:1111-1119. (Pubitemid 23159284)
14. Vijaykumar D, Mao W, Kirschbaum KS, Katzenellenbogen JA. An efficient route for the preparation of a 21-fluoro progestin-16 alpha,17 alpha-dioxolane, a high-affinity ligand for pet imaging of the progesterone receptor. J OrgChem. 2002;67:4904-4910. (Pubitemid 34742724)
15. Moreno-Cantú JJ, Thompson CJ, Zatorre RJ. Evaluation of the ECAT EXACT HR+ 3-D PET scanner in H2(15)O brain activation studies: Dose fractionation strategies for rCBF and signal enhancing protocols. IEEE Trans Med Imaging. 1998;17:979-985. (Pubitemid 128747755)
16. Adam L-E, Zaers J, Ostertag H, Trojan H, Bellemann ME, Brix G. Performance evaluation of the whole-body pet scanner ECAT EXACT HR+ following the IEC standard. IEEE Trans Nucl Sci. 1997;44:1172-1179. (Pubitemid 127827069)
17. Logan J. Graphical analysis of pet data applied to reversible and irreversible tracers. Nucl Med Biol. 2000;27:661-670.
18. Logan J. A review of graphical methods for tracer studies and strategies to reduce bias. Nucl Med Biol. 2003;30:833-844. (Pubitemid 38040992)
19. Westfall PH, Young SS. Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment. New York, NY: John Wiley & Sons, Inc.; 1993.
20. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PGR), by ligand-binding assay compared with ER, PGR and ps2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a southwest oncology group study. Int J Cancer. 2000;89:111-117. (Pubitemid 30185917)
21. Dowsett M, Houghton J, Iden C, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 2006;17:818-826.
22. Allred DC, Carlson RW, Berry DA, et al. NCCN task force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw. 2009;7(suppl 6):S1-S21.
23. Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Beraud T, Gomez F. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women: clinical correlation on 547 patients. Cancer. 1986;57:1171-1180. (Pubitemid 16166228)
24. Alanko A, Heinonen E, Scheinin T, Tolppanen EM, Vihko R. Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer. 1985;56:1696-1700. (Pubitemid 15228524)
25. Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective southwest oncology group study. J Clin Oncol. 1992;10:1284-1291.
26. Khasraw M, Brogi E, Seidman AD. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep. 2011;13:17-25.
27. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of her-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol. 2002;13:1036-1043.
28. Gong Y, Booser DJ, Sneige N. Comparison of her-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer. 2005;103:1763-1769. (Pubitemid 40563246)
29. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of her-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005;93:552-556. (Pubitemid 43079998)
30. Amir E, Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol. 2009;10:933-935.
31. Broom RJ, Tang PA, Simmons C, et al. Changes in estrogen receptor, progesterone receptor and her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res. 2009;29:1557-1562.
32. van de Ven S, Smit VT, Dekker TJ, Nortier JW, Kroep JR. Discordances in er, pr and her2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev. 2011;37:422-430.
33. Namer M, Lalanne C, Baulieu EE. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Cancer Res. 1980;40:1750-1752. (Pubitemid 10102027)
34. Waseda N, Kato Y, Imura H, Kurata M. Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer. Cancer Res. 1981;41:1984-1988. (Pubitemid 11114608)
35. Howell A, Harland RN, Barnes DM, et al. Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res. 1987;47:300-304. (Pubitemid 17002140)
36. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797-2803. (Pubitemid 32538187)
37. Dehdashti F, Mortimer JE, Trinkaus K, et al. Pet-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogenreceptor- positive breast cancer. Breast Cancer Res Treat. 2009;113:509-517.
38. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51-56. (Pubitemid 29137739)
39. Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: A phase 2 randomized study. JAMA. 2009;302:774-780.
40. Mankoff DA, Peterson LM, Tewson TJ, et al. [18f]fluoroestradiol radiation dosimetry in human pet studies. J Nucl Med. 2001;42:679-684. (Pubitemid 32298291)